In 2012, Pfizer’s Deal-Makers Seek Strategic Fit, Financial Discipline, Collaborative Risk-Sharing
This article was originally published in The Pink Sheet Daily
The Big Pharma has the global scale and reach it needs, but will fill in gaps with deals in which it can add “a lot of” scientific value and “incremental” commercial value, says Pfizer’s EVP-Business Development Kristin Peck.
You may also be interested in...
On Building A Better R&D Machine, Part 2: Pfizer’s R&D Chief Mikael Dolsten Talks Partnering Strategy And Accessing Innovation
Since ascending to the top R&D spot at the world’s largest pharmaceutical company, Mikael Dolsten has taken the lead in focusing R&D at Pfizer and optimizing its portfolio. In the second of a two-part interview with "The Pink Sheet" DAILY, Dolsten shares his thoughts on partnering and accessing external opportunities.
The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.